Clinical trials
Phase 1/2 Endometriosis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
12 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 5 |
| Withdrawn | 4 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Annie (Annie) T. Packard | 1 |
| BioGene Pharmaceutical Ltd. | 1 |
| Breath of Life International Pharma Ltd | 1 |
| Jean Schoenen | 1 |
| Jiangsu HengRui Medicine Co., Ltd. | 1 |
| Lebanese University | 1 |
| Mahidol University | 1 |
| Martin Huellner | 1 |
| National Center for Complementary and Integrative Health (NCCIH) | 1 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Endometriosis | 12 |
| Infertility | 2 |
| Pelvic Pain | 2 |
| Adenomyosis | 1 |
| Breast Neoplasms | 1 |
| Carcinoma, Hepatocellular | 1 |
| Carcinoma, Transitional Cell | 1 |
| Disease | 1 |
| Endometritis | 1 |
| Head and Neck Neoplasms | 1 |
Trials
Showing 51 to 12 of 12. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.